Search results
Results from the WOW.Com Content Network
Apixaban, sold under the brand name Eliquis, is an anticoagulant medication used to treat and prevent blood clots and to prevent stroke in people with nonvalvular atrial fibrillation through directly inhibiting factor Xa.
Fig.1) Schematic diagram of the nephron (yellow), relevant circulation (red/blue), and the four methods of altering the filtrate. The nephron is the functional unit of the kidney. [3] This means that each separate nephron is where the main work of the kidney is performed. A nephron is made of two parts:
Reabsorption of glucose in the nephron. The mechanism of action on a cellular level is not well understood. Work is underway to define this mechanism as a prodiuretic with great promise. However, it has been shown that binding of different sugars to the glucose site affects the orientation of the aglycone in the access vestibule. So when the ...
The basic physiologic mechanisms of handling fluid and electrolytes by the nephron - filtration, secretion, reabsorption, and excretion - are labelled. Assessment of kidney function occurs in different ways, using the presence of symptoms and signs , as well as measurements using urine tests, blood tests, and medical imaging.
Side effects may include bleeding, most commonly from the nose, gastrointestinal tract (GI) or genitourinary system. [2] Compared to the risk of bleeding with warfarin use, direct factor Xa inhibitors have a higher risk of GI bleeding, but lower risk of bleeding in the brain. [2]
Diagram outlining movement of ions in nephron, with the collecting ducts on the right. The collecting duct system is the final component of the kidney to influence the body's electrolyte and fluid balance. In humans, the system accounts for 4–5% of the kidney's reabsorption of sodium and 5% of the kidney's reabsorption of water. At times of ...
Diagram illustrating renal flow along the nephron Main article: Excretion In pharmacology , the elimination or excretion of a drug is understood to be any one of a number of processes by which a drug is eliminated (that is, cleared and excreted ) from an organism either in an unaltered form (unbound molecules) or modified as a metabolite.
The second one was apixaban (Eliquis), approved in Europe in 2011 [2] and in the United States in 2012. [3] The third one edoxaban (Lixiana, Savaysa) was approved in Japan in 2011 and in Europe and the US in 2015. [4] Betrixaban (Bevyxxa) was approved in the US in 2017.